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Abbreviations 
ACS  American Cancer Society 
ADAM  Disintegrin And Metalloprotease Family 
AJCC  American Joint Committee of Cancer 
Bcl-2  B-cell CLL/lymphoma 2 
Bcl-X  Anti-apoptotic Gene 
b-FGF  Basic Fibroblast Growth Factor 
BMI  Body Mass Index 
BMP-6  Bone Morphogenetic Protein 6 
c-Myc  Proto-oncogene Retrovirus-associated DNA Sequences 
Cox-2  Cyclooxygenase 2 
DAB-2  Disabled Homolog 2, Mitogen-responsive phosphoprotein 
DPPIV  Dipeptidyl Peptidase IV 
ECM  Extracellular Matrix 
EDTA  Ethylenediaminetetraacetic Acid 
EGFR  Epidermal Growth Factor Receptor 
EMR  Endoscopic Mucosal Resection 
ERCC3  Excision Repair Cross-complementing Rodent Repair Deficiency 
FAP-  Fibroblast Activation Protein- 
FAS-L  Fas Ligand (TNF superfamily, member 6) 
GERD  Gastroesophageal Reflux Disease 
GUS  Beta-Glucuronidase 
HER2  Human Epidermal Growth Factor Receptor 2 
HET1A  Immortalized Esophageal Keratinocytes (Cell Line) 
HPV  Human Papillomavirus 
hTERT  Human Telomerase Reverse Transcriptase 
HUVEC  Human Umbilical Vein Endothelial Cells 
iNOS  Inductible Nitric Oxide Synthase 
INT-2  Fibroblast Growth Factor 3 
KYSE  Human Japanese Esophagus Carcinoma Squamous Cell (Cell Line)
MMP  Matrix Metalloproteinase 
MT-MMP  Membrane-type Matrix Metalloproteinase 
Nd:YAG  Neodymium-doped Yttrium Aluminium Garnet  
NFB  Nuclear Factor Kappa B 
NSAID  Non-steroidal Anti-inflammatory Drug 
P16  Tumor Suppressor Gene 
p16MST1  Tumor Suppressor Gene 
PCR  Polymerase Chain Reaction 
PDT  Photodynamic Therapy 
PVDF  Polyvinilydene Fluoride 
QRT-PCR  Quantitative Real-time Polymerase Chain Reaction 
RAR  Retinoic Acid Receptor Beta 
RFA  Radiofrequency Ablation 
RT-PCR  Real-time Polymerase Chain Reaction 
SCC  Squamous Cell Carcinoma 
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SIM  Specialized Intestinal Metaplasia 
SIMP  Serine-type Integral Membrane Peptidase Family 
TBS  Tris Buffered Saline 
TGF-  Transforming Growth Factor Alpha 
TGF-  Transforming Growth Factor Beta 
TGH  Triiodothyronine, Glucagon and Heparin Mixture 
TNM  Classification of Malignant Tumors 
TP  Thymidine Phosphorylase Gene 
TRAIL  Tumor Necrosis Factor-related Apoptosis-inducing Ligand 
TRIS  Tris(hydroxymethyl)aminomethane 
UICC  International Union Against Cancer 
uPA  Urokinase-type Plasminogen Activator 
uPAR  Urokinase-type Plasminogen Activator Receptor 
VEGF  Vascular Endothelial Growth Factor 
WHO  World Health Organization 
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TNM Classification / Staging 
Histological classification of carcinomas according to UICC Global Cancer Control, 
TNM Atlas (UICC 2005).  
 
Anatomical subsites of the esophagus: 
- Cervical esophagus 
- Intrathoracic esophagus 
1. Upper thoracic portion 
2. Mid-thoracic portion 
3. Lower thoracic portion 
T – Primary Tumor 
 
Tx Primary tumor cannot be assessed  
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor invades lamina propria or submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades adventitia 
T4 Tumor invades adjacent structures 
 
N – Regional Lymph Nodes 
 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph nodes metastasis 
N1 Regional lymph node metastasis 
 
Regional lymph nodes: 
- Cervical esophagus: 
- Scalene 
- Internal jugular 
- Upper and lower cervical 
- Periesophageal 
- Supraclavicular 
 
- Intrathoracic esophagus: 
- Upper periesophageal 
- Subcarinal 
- Lower periesophageal 
- Mediastinal lymph nodes 
- Perigastric lymph nodes
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M – Distant Metastasis 
 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
Tumors of the upper thoracic esophagus: 
M1a Metastasis in cervical lymph nodes 
M1b Other distant metastasis 
 
Tumors of the mid-thoracic esophagus: 
M1a Not applicable 
M1b Non-regional lymph nodes or other distant metastasis 
 
Tumors of the lower thoracic esophagus: 
M1a Metastasis in celiac lymph nodes 
M1b Other distant metastasis 
 
pTNM – Pathological Classification 
 
The pT, pN and pM categories correspond to the TNM categories (UICC 2005). 
 
AJCC/UICC Stage Grouping for Esophageal Cancer (AJCC 2002, UICC 2005)
 
Cancer 
Stage 0 - Tis N0 M0 
Stage I  - T1 N0 M0 
Stage IIA - T2 N0 M0 
T3 N0 M0 
Stage IIB - T1 N1 M0 
T2 N1 M0 
Stage III - T3 N1 M0 
T4 Any N M0 
Stage IV - Any T Any N M1 
Stage IVA - Any T Any N M1a 
Stage IVB - Any T Any N M1b 
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3. GENERAL INTRODUCTION 
 
Once the diagnosis of cancer is established, it is of utmost importance to determine 
whether the disease is local or already has spread to lymph nodes or distant organs 
(Fidler & Ellis 1994). Some scientists suggest that in nearly 50% of patients, surgical 
excision of primary malignant tumors is not curative because metastases have already 
occurred by that time (Sugarbaker et al. 1977, Sugarbaker 1979, Fidler & Balch 
1987). Currently, metastases are the cause of 90% of human cancer mortality (Mehlen 
et al. 2006). Recent studies and clinical experiences show that metastases without any 
doubt are the most dreaded aspect of cancer.  
 
In the 20th century, many different hypotheses about metastases were put forward. 
One of the first approaches was Stephen Paget’s “seed and soil” hypothesis (Paget 
1889), describing organs that are affected by disseminated cancer. Later, scientists 
such as James Ewing, Dale Rex Coman, Irving Zeidman, Barbara Lucke and others, 
suggested different theories about the origin of metastases (Fidler 2003). Isaiah J. 
Fidler reported in 1970-1973 that metastasis can result from the survival of only a few 
tumor cells (Fidler 1970, Weiss 1986, Fidler 1990). After the year 2000, research 
concerning tumor progression and metastasis development confirmed the theory that 
at the time of diagnosis, many human tumors are heterogeneous and include numerous 
cell subpopulations. The tumors also contain the so-called “cancer stem cells”, which 
display different biological characteristics and metastatic potential (Bonnet & Dick 
1997, Fidler 2003).   
 
Today, research on malignant expansion is in progress and mainly concentrates on 
early cancer diagnosis and cancer therapy directed against host factors – angiogenesis 
and organ growth factors, as it is believed to provide a basis for treatment that will 
give better results than conventional therapy (Simone et al. 1998, Fidler 2003). 
 
As mentioned above, there are many hypotheses and approaches trying to shed light 
upon the process of neoplastic disease development. Some of the theories focus 
particularly on the formation of metastases from the primary tumor through an 
exceedingly complex process. It includes a series of sequential steps such as invasion 
of adjacent tissue, intravasation, transport through the circulatory system and arrest at 
a secondary site, extravasation and growth in a secondary organ (Folkman 1986, 
Liotta 1986, Nicolson 1988). To complete this process, degradation of the 
extracellular matrix (ECM) is decisive (Folkman 1986, Takino 2007). Basic and 
clinical research has therefore been concentrated on the role of tumor-associated 
proteolytic systems – proteases and anti-proteases, particularly membrane proteases. 
Some of the most extensively studied proteases are dipeptidyl peptidase IV (DPPIV), 
urokinase-type plasminogen activator (uPA) and, recently, seprase (surface expressed 
protease, also known as fibroblast activation protease FAP-Vivier et al. 1991, 
Morimoto et al. 1994, Hansen et al. 1994, Rettig et al. 1994, Scalan et al. 1994, 
Mathew et al. 1995, Chen 2003, Chen & Kelly 2003	
 
Many studies have shown that in several tumors the expression of membrane 
proteases in cancer cells or stromal cells adjacent to cancer sites correlates with an 
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increasing tumorigenicity (Nishino et al. 1988, Scalan et al 1994, Nekarda et al. 1998, 
Okada et al. 2003, Iwasa et al. 2003, Kikkawa et al. 2005). However, the 
pathophysiologic significance of the serine proteases in esophageal carcinoma has not 
yet been fully elucidated. 
Epidemiology of esophageal cancer 
 
Esophageal cancer is turning into one of the more common cancers in the world. The 
incidence shows great geographical variations, but on the whole it is stated to be 
number six in frequency (Stewart & Kleihues 2003, Siewert et al. 2004, NCI 2006). 
The majority of cases are diagnosed in developing countries, where it is the fourth 
most frequently occurring cancer. The area with the highest reported incidence is 
known as the “Esophageal cancer belt of South-Central Asia”, which extends from 
Turkey through northern Iran, Afghanistan and southern Russia to northern China 
(Ghadirian 1982, Saidi 1999, Hajian 2002). The invasive cancer incidence rate in 
these areas is more than 200 per 100 000 inhabitants, compared to Europe and the 
USA where it is 2.6-11.1 cases and 2.6-5.9 cases per 100 000 inhabitants respectively, 
with considerable racial and regional differences (NCI 2006). In particular, the area 
located in the southern part of the Taihang Mountains on the borders of Henan, Shansi 
and Hopei provinces in China has one of the highest incidence and mortality rate for 
esophageal carcinoma in the world. In Linxian county in Henan province, the age-
adjusted mortality rate for esophageal carcinoma has been reported to be 151/100 000 
for males and 115/100 000 for females (Lu et al. 1988, Stoner et al. 2001, He et al. 
2008). 
 
There are two different histological types of esophageal carcinoma: squamous cell 
carcinoma (SCC) and adenocarcinoma (AC). In Western countries, the number of 
SCCs and ACs is almost equivalent, while in developing countries, SCC is the most 
prevalent one (Pera et al. 1993, Devesa et al. 1998, Blot & McLaughlin 1999, Daly et 
al. 2000, Corley et al. 2001, Parkin et al. 2002,  Pera et al. 2005, de Jonge et al. 2006, 
Yee et al. 2007, Holmes et al. 2007). 
 
Since the entire esophageal tract is normally lined with squamous epithelium, SCC 
can occur anyplace along the length of the esophagus. AC, on the other hand, starts in 
tissue lined by columnar epithelium, which normally does not cover the esophagus. In 
order for an AC to develop, columnar epithelium must replace an area of squamous 
epithelium in a metaplastic process (Barrett’s metaplasia), often followed by dysplasia 
(non-invasive neoplastic transformation with a potential for malignant progression). 
This occurs mainly in the lower esophagus, where most ACs are found (Stein et al. 
1993, Cote et al. 2003, de Jonge et al. 2006). 
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Squamous cell carcinoma 
 
The esophagus is normally lined with stratified squamous nonkeratinizing epithelium 
(Fig.1A) (Norton et al. 2000). SCC arises from this epithelial layer, probably in 
response to chronic toxic irritation. In many cases, esophageal SCC is the end result 
of a progression through increasingly severe degrees of dysplasia to carcinoma in situ, 
resulting in invasive carcinoma (Fig. 1B). Clinical and epidemiological studies have 
confirmed that squamous epithelial dysplasia of the esophagus is a precancerous 
lesion and that approximately 70% of patients with squamous dysplasia later develop 
SCC (Mukada et al. 1978, Munoz et al. 1982, Mandard et al. 1984, Kuwano et al. 
1988).  
 
Epithelial dysplasia has previously been classified into low-, moderate- and high 
grades (Oehlert et al. 1979, Riddell et al. 1983, Tosi et al. 1989, de Dombal et al. 
1990, WHO 1990, Lewin & Appelman 1996). Low grade dysplasia usually affects 
less than half of the epithelial thickness, while high grade dysplasia affects more than 
half of it. Moderate grade dysplasia is borderline or intermediate between the two 
other grades. Sometimes, separating one grade from another is difficult, as the lines of 
demarcation are not always clear. Nowadays, many chose to use thus the two-grade 
system, low- and high grade dysplasia (Riddell et al. 1983, Tosi et al. 1987 & 1989, 
Rubio et al. 1989, de Dombal et al. 1990, Burke et al. 1991).  
 
When it comes to the transition from high grade dysplasia to carcinoma in situ, no 
clear distinction can be made either macro- or microscopically. Both stages display a 
similar histological pattern and probably require similar surveillance and treatment 
(Lewin et al. 1998).  
Microscopic features   
 
Preinvasive lesions are characterized by cellular atypia and abnormal intraepithelial 
architecture. These features progress until atypical cells have spread to all epithelial 
layers and the architecture no longer can be identified. These characteristics are 
clearly visible in high grade dysplasia (carcinoma in situ), whereas low grade 
dysplasia still has a component of differentiated squamous cells in the upper layers, 
and abnormal cells are limited to the lower half of the epithelium (Crissman et al. 
1987 & 1989, Mills et al. 2000, WHO 2000).  
 
The histologic appearance of invasive SCC is related to invasion of atypical cells into 
lamina propria or beyond it (Schlemper et al. 1997). Usually, a large pushing front of 
numerous cohesive squamous cells can be observed, but the cells may also invade as 
small cell nests or as individual cells infiltrating through the stroma. Invasive 
carcinomas generate a surrounding inflammation, where a mixture of various 
leukocytes can be observed (Fig. 1B and 1C) (Crissman et al. 1987 & 1989, WHO 
2000). 
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Risk factors 
 
Use of tobacco and alcohol are among the highest risk factors regarding SCC. 
Consumption of salty and spicy food, as well as low fiber intake have also been 
positively identified as risk factors for developing SCC (Soler et al. 2001, Enzinger & 
Mayer 2003, Syrjänen 2002, Green et al. 2003). Further risk factors are summarized 
in Table 1. 
 
Adenocarcinoma 
 
In contrast to SCC, the incidence of AC nowadays is rising rapidly to the point where 
this tumor accounts for 50% or more of all esophageal cancers in the USA and other 
industrialized countries (Lagergren et al. 1999, Bollscheweiler 2001, de Jonge et al. 
2006, Merry et al. 2007, Hashibe et al. 2007). ACs occur almost exclusively in the 
distal part of the esophagus. The tumor is first seen as a thickened plaque-like white 
mucosa. Larger lesions form white exophytic polypoid masses with well demarcated 
borders. Occasionally, carcinomas appear papillary or may be multifocal. AC spreads 
through the esophagus into periesophageal tissues (Fenoglio-Preiser et al. 1989).  
 
Microscopic features 
 
The majority of ACs is classified as low-, moderate to well differentiated carcinomas 
and form glands with columnar epithelium. The epithelial cells contain nuclei with a 
coarse chromatin pattern, nucleoli and cytoplasm in which mucin can be found (Fig. 
1F). A minority of tumors displays the diffuse type pattern with signet ring cells 
(Petterson 1932, Adams et al. 1945, Spin 1973, Thompson et al. 1983, Thurberg et al. 
1999, Nakagawa et al. 2000).  
 
Risk factors 
 
The major acknowledged risk factor for AC is the pathological and clinical alteration 
of the lower esophagus, also known as Barrett’s esophagus, coexisting with 
gastroesophageal reflux disease (GERD), wherein columnar epithelium replaces the 
squamous epithelium that normally lines the distal esophagus (Lagergren et al. 1999, 
Heath et al. 2000, Ye et al. 2004, Nakajima & Hattori 2004, Oberg et al. 2005, Layke, 
et al. 2006). Other risk factors are summarized in Table 1. 
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Table 1. Risk factors for esophageal carcinoma. 
 
 
SCC 
 
 
AC 
 
Tobacco smoking* 
 
 
GERD 
Alcohol consumption 
 
Barrett’s esophagus 
Consumption of salt-cured, salt-pickled and 
moldy food** 
 
High BMI 
 
Tobacco smoking* 
Low fiber intake 
 
 
Use of NSAID 
Consumption of hot beverages 
 
 
Work in stooped posture 
Achalasia 
 
 
Genetic alterations 
Previous head and neck cancer 
 
 
Plummer-Vinson syndrome 
 
 
HPV (human papilloma virus) infection 
 
 
Genetic alterations 
 
 
 
* Nitrosamines, polycyclic aromatic hydrocarbons, aromatic amines, aldehydes and 
phenols 
** Nitrosamines and fungal toxins 
 
Barrett’s esophagus 
The importance of Barrett’s esophagus rests on the fact that local occurrence of 
columnar metaplasia can develop into AC. The concept of Barrett’s esophagus has 
changed significantly since its first description by Numan R. Barrett in 1950 and 1957 
(Barrett 1950 & 1957). In 1950, in “Chronic Peptic Ulcer of the Oesophagus and 
Oesophagitis”, Barrett reviewed several published cases, looked at preserved 
pathologic specimens and found that esophageal ulcers were surrounded by columnar 
mucosa. He concluded that “these cases were examples of congenital short esophagus 
– in which part of the stomach extends upwards into the mediastinum, or even to the 
neck, and that in this stomach a typical chronic gastric ulcer can form”. He suggested 
that the ulcer was a separate entity from reflux esophagitis (Barrett 1950, Cameron 
2001). In 1957, Barrett revised his theory and noted that the columnar lining was a 
continuous sheet extending from the esophago-gastric junction upwards, and that it 
was thus columnar cell-lined esophagus extending into the mediastinum and not the 
stomach (Barrett 1957). As a result of these observations, the term “Barrett’s 
esophagus” has become well established in medical literature to indicate columnar 
metaplasia of the distal esophagus associated with chronic GERD. Ever since, several 
different concepts of Barrett’s esophagus have emerged (Cohen et al. 1963, Trier 
1970, Bremner et al. 1970, Naef & Savary 1972, Iascone et al. 1983, Gillen et al. 
1988).  
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Based on the potential development of malignancy, the heterogenous spectrum of 
Barrett’s metaplastic mucosa is classified into two distinct types: columnar 
epithelium, with specialized intestinal metaplasia (SIM), including goblet and 
columnar non-goblet cells, and columnar epithelium, without specialized intestinal 
metaplasia and lacking goblet cell-type elements (Barrett 1957, Siewert & Dittler 
1993, Koppert et al. 2005, Fléjou 2005). The goblet cells are presently regarded as the 
hallmark in the histological identification of Barrett’s esophagus and in the selections 
of high-risk patients for endoscopic surveillance (Chaves et al. 1999). The columnar 
epithelium with SIM is the most common and distinctive epithelium type found in 
Barrett’s esophagus (Fig. 1D) (Spechler et al. 1994, Spechler 2003). 
 
Dysplasia in Barrett’s esophagus 
 
Dysplasia in Barrett’s esophagus can be classified as low-, moderate or high grade. In 
low grade dysplasia, simple tubules with little branching can be demonstrated. 
Atypical cells are present in the glands, and the epithelium is usually pseudostratified. 
Mitotic figures usually are sparse but can be present in the superficial half of the 
mucosa (Lewin 1998, Goldblum 2003).  
 
High grade dysplasia (carcinoma in situ) shows severe cellular atypia and varying 
degrees of abnormal architecture. The nuclei are often enlarged, vesicular with 
irregularly clumped chromatin and contain large, distinct and irregular nucleoli (Fig. 
1D and 1E) (Smith et al. 1984, Schmidt et al. 1985, Spechler & Goyal 1986, Reid et 
al. 1988). Moderate grade dysplasia is a borderline condition between low- and high 
grade dysplasia. 
 
Macroscopic appearance of Barrett’s esophagus 
 
Endoscopy reveals columnar epithelium in the distal esophagus with a characteristic 
red color which contrasts sharply with the pale appearance of adjacent squamous 
epithelium (Spechler & Goyal 1996). Although endoscopic examination can usually 
distinguish columnar epithelium from squamous epithelium, it is difficult to tell apart 
different types of columnar epithelium by endoscopic appearance alone. SIM and 
gastric columnar epithelium can only be distinguished by histological examination of 
biopsy specimens. Gastric epithelium may normally line a short segment of the distal 
esophagus. Thus, endoscopists usually diagnose Barrett’s esophagus only when 
columnar epithelium extending well above the gastroesophageal junction can be 
verified. The criteria for diagnosing Barrett’s esophagus based on the length of the 
columnar lining have varied, ranging from 2-5 cm or more, measured above the 
gastroesophageal junction. Nowadays, we distinguish only two types of Barrett’s 
esophagus: the long segment, where columnar lining extends more than three cm from 
the gastroesophageal junction, and the short segment, where columnar lining extends 
up to three cm from the gastroesophageal junction (Schnell et al. 1992, Levine et al. 
1993, Spechler 1994 & 2003, Hirota et al. 1999, Spechler & Goyal 1996).  
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Figure 1. Microscopic illustrations of SCC and AC (original magnification x 200).  
Normal esophageal epithelium (A). Transition of normal esophageal epithelium toward SCC 
(B). Well differentiated SCC (C). Barrett’s esophagus with intestinal metaplasia within 
columnar epithelium (D). High grade dysplasia within columnar epithelium (E). Moderately 
differentiated AC (F).  
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Early esophageal cancer  
 
Early-stage esophageal cancer is almost asymptomatic with minimal findings in 
endoscopy. However, a risk for malignant spreading into vessels and lymph nodes is 
present even in small tumors (Peters et al. 1994, van Sandick et al. 1998, Stein et al. 
2000 & 2005, Buttar et al. 2001). 
 
The accepted definition of early esophageal cancer is based on two related elements: 
superficial extension of the tumor in mucosa and submucosa, and complete or almost 
complete absence of lymph node metastasis. Most cases correspond therefore to stage 
I cancer (T1N0M0), according to the TNM/AJCC/UICC staging system (see above) 
(AJCC 2002, UICC 2005).  
 
This definition does not apply to all superficial SCC tumors (T1). The lymph node 
involvement is negligible only when the tumor is limited to the mucosa. There are 
three successive phases in the invasion of mucosa: intraepithelial cancer (carcinoma in
situ), without affection of the basal membrane; microinvasive cancer with invasion 
into lamina propria; and intramucosal / transmucosal cancer, invading the muscularis 
mucosa. No spreading to lymph nodes is associated with intraepithelial cancer, and 
only a small number of lymph nodes can present metastasis in microinvasive cancer. 
Intramucosal cancer presents a higher degree of lymph node metastases and reaches 
the submucosal mucous glands through intraductal propagation (Hölscher et al.1997, 
Ell et al. 2000, Rice et al. 2001, May et al. 2002, Stein et al. 2003). 
 
Severe dysplasia is considered as carcinoma in situ and is often found in patients with 
multicentric esophageal cancer. Tumors extending into the submucosa have a risk rate 
for lymphatic invasion varying from 30% to 50%. Submucosal SCC cannot be 
considered as an early cancer, but must instead be treated as an advanced cancer 
(Streitz et al. 1991, Nigro et al. 1999, Tajima et al. 2000, Buskens et al. 2004). In AC 
that has developed in columnar cell-lined esophagus, a clear-cut distinction between 
superficial (T1) and non-superficial (T2) cancer is based on whether it invades the 
muscularis propria or not (Lambert R, 1995, Hölscher et al.1997). 
 
Esophageal cancer diagnostics 
 
Direct diagnostic techniques: 
- Esophagoscopy with biopsy followed by a pathological evaluation 
- Barium X-ray 
- Computed tomography with multi-slice technique 
 
Diagnostic techniques used to determine the extent of disease: 
- Endoscopic ultrasound 
- PET and PET/CT scans 
- Bronchoscopy 
- Thoracoscopy and laparoscopy 
 
 23
Esophageal cancer research areas 
It is well known that several environmental factors can lead to the development of 
esophageal carcinoma. Environmental carcinogens are able to affect the genetic 
material of host cells, generating an abnormal regulation of multiple genes (Stoner et 
al. 2007). Genetic alterations observed in esophageal carcinomas are based on 
alterations in tumor suppressor genes leading to uncontrolled cell proliferation and 
terminating apoptosis, loss of cell cycle control as a result of disruption of G1/S cell 
cycle checkpoints and changes in oncogene functions leading to deregulation of cell 
signaling pathways (Stoner et al. 2007). Several previous studies have reported 
numerous genetic alterations associated with esophageal carcinomas, as summarized 
in Table 2 (Lu et al. 1988, Hollstein et al. 1988 & 1991, Jiang et al. 1993, Guo et al. 
1993, Gao et al. 1994, El-Rifai et al. 1998, Moskaluk 1998, Tanaka et al. 1999, 
Hiyama et al. 1999, Xing et al. 1999, van Dekken 1999, Raida et al. 1999, 
Zimmermann et al. 1999, Kimura et al. 1999, Lu 2000, Mandard et al. 2000, Selaru 
2002, Kuwano et al. 2005).  
 
The discovery of new tumor cell markers, e.g. growth factor receptors, angiogenetic 
and apoptotic factors or transmembrane proteases, has become an important current 
research topic (Table 3) (Gottlinger et al. 1986, Robaszkiewicz et al.1991, Reid et al. 
1992 & 2000, Traweek et al. 1993, Galipeau et al. 1996, Teodori et al. 1998, Hanahan 
& Weinberg 2000, Lam 2000, Mandard et al. 2000, Blant et al. 2001, Xu Y et al. 
2002, Klein et al. 2002, Yu et al. 2003, Hosch et al. 2003). The expression differences 
in molecular markers in premalignant and malignant tumor stages, as well as in 
various histological tumor types are essential for the development of more effective 
and early diagnostic methods and less harmful therapies for esophageal carcinoma.  
 
In combination with surgery, gene therapy, immunotherapy and new types of 
chemotherapy, including tyrosine kinase inhibitors or examination of new 
combinations of existing drugs with irradiation (multimodal therapy), are the current 
treatment trends (Shaheen & Ransohoff 2002, AJCC 2002, Enzinger & Mayer 2003, 
Swisher et al. 2003, Burmeister et al. 2005, Kleinberg et al. 2004, Koshy et al. 2004, 
Posner et al. 2005, Souza & Spechler 2005, ACS 2008). 
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Table 2. Genetic alterations associated with esophageal carcinoma (modified after Stoner &  
Gupta 2001).  
 
 
 
SCC 
 
 
p53 mutations 
Loss of p16MST1 and / or p15, and / or RAR and disabled-2 (DAB-2) 
Amplification of INT-2, EGFR, cyclin D1 and c-Myc 
Altered expression of the cyclin D1 
Altered expression of apoptosis related genes: bcl-2, caspase 3, TRAIL, Fas-L, Fas 
Elevations in hTERT, BMP-6, iNOS, COX-2 and -catenin levels 
Loss of heterozygosity on chromosomes 1p, 3p, 4, 5q, 9, 11q, 13q, 17q and 18 
Enhanced expression of the transcription activator, NFB 
 
 
AC 
 
 
Gains of chromosomes 6p, 7pq, 8q, and 17q  
High-level amplifications at 8q23 q24.1, 15q25, 17q12q21 and 19q13.1  
Losses of chromosomes 4pq, 5q, 18q, 19p, 20, 21, and Y 
 
 
 
Table 3. Molecular markers in esophageal cancer (modified after Stoner & Gupta 2001).  
 
 
Markers 
 
 
Growth factor receptors 
    EGFR 
    HER2/neu 
 
Angiogenetic factors 
    Cox-2 
    TP 
    VEGF 
    b-FGF 
    TGF-TGF-   
 
Cell cycle regulators 
    Cyclin D1 
    p21, p27, p53 
     
 
Apoptotic factors 
    Bcl-2 
    Bcl-X 
    P16 
    Survivin 
 
DNA repair system 
    ERCC3 
 
Matrix metalloproteinases 
    MMP-2, MMP-7, MMP-9    
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Treatment of esophageal carcinoma 
 
Single modality treatments 
Surgery
Surgical resection has long been the mainstay of curative treatment and remains the 
standard treatment for stage T1-T3, N0, M0 tumors. It is contra-indicated in locally 
advanced tumors (T4) and when lymph node and distant metastases have developed 
(Fumagalli 1996, Veuillez et al. 2007). Total or partial esophagectomy is most 
commonly performed on esophageal and gastric cardia carcinomas, as well as in 
patients with Barrett’s esophagus associated with severe dysplasia, undilatable 
strictures and benign, obstructing tumors (Fumagalli 1996). 
Usually, resection of the thoracic esophagus is made by a right- or left-sided 
transthoracic ‘en bloc’ resection. A transhiatal resection is an option for cancer of the 
distal part of the esophagus (Skinner 1983, Orringer 1984, Killinger et al. 1996, 
Veuillez et al. 2007). 
 
Esophageal cancer involves a risk for lymph node metastasis development, and the 
quality of the lymphadenectomy associated with esophagectomy is therefore 
important. Two-field lymphadenectomy (thoracic and abdominal) for cancers from 
the distal and middle part of the esophagus and three-field lymphadenectomy 
(thoracic, abdominal and cervical) for cancers of the proximal part of the esophagus 
are recommended (Fumagalli 1996, Lerut et al. 2004, Veuillez et al. 2007).  
The results depend on the extension of the disease, possible co-morbidities and the 
surgeon’s experience. The post-operative mortality rate currently ranges from 4% to 
10%, depending on the surgical centers (patient volume and team experience) 
(Collard et al. 2001, Bumm & Wong 1994). After R0 resection, the reported 5-year 
overall survival rate is greater than 95% for stage 0, between 50% and 80% for stage I, 
30% and 40% for stage IIA, 10% and 30% for stage IIB and between 10% and 15% 
for stage III (Enzinger & Mayer 2003, NCI 2006,  Veuillez et al. 2007).  
Endoscopic Mucosal Resection 
This method is restricted to superficial cancers limited to the mucosa, submucosa or 
precancerous lesions and is not recommended for tumors invading the muscularis 
mucosa or if lymph node metastasis is suspected. The procedure is usually performed 
after confirmation of the extent of the lesion by iodine staining. An endoscopic 
mucosal resection (EMR) tube with a snare which seizes the lifted mucosa including 
its lesion is used. Finally, the mucosa is resected by electric current (Makuuchi et al. 
1992, Yokoyama et al. 1995, Makuuchi1996).  
 
The rate of success is more than 90% when indications are respected, and the 
immediate morbidity rate is low (perforation less than 1%, death 0.1%). However, 
delayed complications are more common and are reported in about 6% of cases 
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(stenosis, recurrences, bleeding) (Kodama et al. 1998, Inoue 1998, Veuillez et al. 
2007).  
 
The problems arise when the lesion is not completely removed and additional excision 
is needed such as piecemeal resection carrying the possibility of tumor tissue 
implantation. In these cases, supplementary treatments such as photodynamic therapy 
and radiofrequency ablation (RFA) are often warranted. 
Laser therapy 
Laser therapy is today considered a palliative endoscopic therapy (Spencer et al. 
2002). The tumor is vaporized or coagulated under direct vision with no mechanical 
stress on the esophageal wall. This technique is suitable for patients with exophytic 
tumors. Successful tumor recanalization can be achieved in more than 90% of the 
patients, and a subsequent return to eating solids can be obtained in the majority. 
Laser therapy does, however, need to be repeated every 4–6 weeks as the tumor re-
grows. This problem may be solved by combining it with adjuvant radiotherapy 
(Spencer et al. 2002). Palliative laser therapy has largely been replaced by self-
expanding stents or been combined with these. 
Photodynamic therapy 
Photodynamic therapy (PDT) is generally used with the intent of curing early stages 
of esophageal cancer and as a palliative treatment for advanced and recurrent cancers. 
PDT is initiated with the administration of a photosensitizer (sodic porfimere, 5-ALA, 
meta-tetra hydroxyphenyl chlorine) and local tumor treatment is activated later using 
appropriate laser monochromatic light (Sibille et al. 1995, Veuillez et al. 2007).  
The advantage of some of the PDT drugs is that they destroy cancer cells with less 
harm to normal cells. One drawback is that the photosensitizer must be activated by 
laser light; therefore only superficial cancers can be treated. The light cannot reach 
cancers that have expanded deeper into the esophageal wall or spread to other organs. 
As a palliative therapy, PDT does not eliminate all cancer tissue, but partially removes 
it and relieves the dysphagia. 
When PDT is used on superficial cancers, the rate of success for this technique is 
approximately 100% but, depending of the drug used, includes a risk for symptomatic 
stenosis in nearly one-third of the cases (Barr 2003). In a single study, the 5-year 
survival rate was 74% (Sibille et al. 1995). 
 
PDT, EMR and RFA, either alone or in combination, are simple, efficient and non-
mutilating procedures that could be used on all localized lesions defined by a battery 
of markers to be precancerous even in patients with severe co-morbidity. 
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Multimodal treatment 
Radio- and chemotherapy 
When surgery is contra-indicated and the patients have no signs of distant metastases, 
infiltrating esophagus cancers may be treated using radio- and chemotherapy 
(Veuillez et al. 2007). The first report, by Herskovic in 1992, demonstrated that 
combined platinum-based radio- and chemotherapy treatment (50 Gy + five days with 
infusion of 5-fluorouracil (5-FU) and one day of cisplatin), followed by two cycles of 
the same chemotherapy regimen, generated better results than external irradiation 
alone. The radio- and chemotherapy combination resulted in a 25% 5-year overall 
survival rate compared to 0% for radiotherapy alone (Herskovic et al. 1992, Al-Sarraf 
et al. 1997). This study established the radio- and chemotherapy combination as a 
standard treatment for localized esophageal cancer (Stages II and III) (Veuillez et al. 
2007). Other investigations, however, showed that there was no benefit in terms of 
overall survival in favor of secondary resection for patients responding to radio- and 
chemotherapy combination treatment (Stahl et al. 2005, Bedenne et al. 2007).  
 
Recently, recommendations on the multimodal treatment (surgery and 
chemoradiation) of esophageal carcinoma have been published by Seitz and have been 
proposed as a general strategy for treatment of esophageal cancer (Seitz et al. 2006). 
Superficial cancers (in situ or T1-m1 or T1-m2, where “m” stands for the degree of 
infiltration into the mucosa) do not require multimodal treatment. Tumors covering 
more than two cm may be treated by mucosectomy. However, if the pathological 
examination reveals a more invasive tumor (T1-m3 or T2) with a risk for lymph node 
metastasis development, additional treatment is necessary and esophagectomy or 
radio- and chemotherapy combination has to be discussed depending on the condition 
of the patient. 
 
Stage I (T1–T2, N0) invasive intrathoracic cancers are subject to surgical resection as 
standard treatment. In case of lymph node metastasis, adjuvant chemotherapy may be 
considered. In case of contra-indications to surgical resection, a radio- and 
chemotherapy combination may be appropriate. 
 
Stage II (T1N1, T2N1, T3N0) invasive intrathoracic cancers usually undergo surgical 
resection preceded by neoadjuvant chemotherapy as standard treatment. Contra-
indications to surgery entail the administration of radio- and chemotherapy. 
 
Stage III (T3N1, T4N0-N1) intrathoracic invasive SCCs are subject to radio- and 
chemotherapy as standard treatment. In case of incomplete response or early 
recurrence, a salvage surgical excision must be considered.  
 
Regarding AC, neoadjuvant chemotherapy before and after surgical resection is a 
valid option and by many considered the standard treatment (Cunningham et al. 
2006). Locally inoperable cancers may be treated with a radio- and chemotherapy 
combination. 
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Radio- and chemotherapy combination is recommended when surgical resection is not 
possible for cervical cancers. 
 
Non-operable patients without metastasis usually undergo a radio- and chemotherapy 
combination or receive an esophageal stent and occasionally an endotracheal stent in 
addition. The choice of treatment depends on the presence of esophago-tracheal or 
bronchial fistulae. 
 
Patients with metastatic disease may be treated with radiotherapy or radio- and 
chemotherapy. An esophageal stent followed by chemotherapy is another option. 
 
Common to all regimens is a disappointing low 5-year survival rate when clinical 
signs of cancer initiate treatment. Future strategy directed against symptoms (reflux) 
and dysplasia signs in premalignant lesions, combined with markers of malignant 
development and local treatment could improve the survival rate. 
 
Palliative treatment 
 
Stenting has become the treatment of choice for strictures with inoperable esophageal 
cancer (Guo et al. 2007 & 2008). However, stricture recurrence remains a challenge 
after a stent placement. Previously, endoscopic insertion of rubber stents was the first 
choice, but more recently, expanding metal stents have been introduced, as they are 
easier and safer to insert and less initial dilatation is required. Once in position, they 
expand across the tumor, but as experience shows, the swallowing quality is often not 
better, and the patients may have as many problems as with the rubber stents (Spencer 
et al. 2002). 
 
Tumor invasion and development of metastases 
Tumor invasion into the collagenous matrix and metastases represent the main 
problems in the treatment of carcinoma patients. The majority of patients with newly 
diagnosed carcinomas already present clinically detectable metastases (Fidler et al. 
1978, Fidler & Hart 1982, Fidler & Balch 1987, Weiss 2000). In the tumor invasion 
process, cancer cells infiltrate the adjacent ECM by using several types of matrix 
degrading enzymes such as metalloproteinases, cysteine-, aspartic-, threonine and 
serine proteinases (Fig. 2) (Duffy 1987, Zukker 1988, Brunner & Preissner 1994, 
Keppler et al. 1994, Sloane et al. 1994, MacDougall & Matrisian 1995, Birkedal-
Hansen 1995, Hewitt & Danø 1996). These enzymes are produced by the tumor cells 
and / or the surrounding host cells, and they cooperate with other proteins, for 
example integrins, cadherins and immunoglobulins, which may facilitate the 
dissolution process of the ECM (Hynes 1992, Natali et al. 1992, Morino et al. 1995, 
Takeichi 1991 & 1995 Rucklidge et al. 1994).  
Next, neovascularization takes place, and cancer cells subsequently invade blood 
vessels in order to move to another organ. Adherent to the blood vessel walls, 
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malignant cells leave the primary circulation and migrate into the neighboring tissue, 
in a process called extravasation. They thus establish a new tumor site in the 
organism. The metastatic process is characterized by a highly selective competition, 
favoring the survival of a small subpopulation of metastatic cells (Liotta 1986, Fidler 
& Hart 1982). The metastatic subpopulation is abundant in the primary tumor tissue 
early in its growth, but less than 0.01% of malignant cells entering circulation actually 
form metastases (Kerbel et al. 1990, Fidler & Ellis 1994). 
 
Figure 2. Invasive carcinoma development (modified after Liotta & Kohn 2001). 
 
Membrane proteases 
Membrane-bound proteases are widely spread among the different cell systems. Their 
expression in particular cell types is finely regulated, reflecting the specific functional 
cell implications and engagement in defined physiological pathways (Sedo et al. 
2001). It has been reported that the proteases play a crucial role, both as effectors and 
regulatory molecules in protein turnover, ontogeny, inflammation, tissue remodeling, 
cell migration and tumor invasion (Sedo et al. 2001).  
 
Several families of membrane proteases have been identified on the basis of their 
proteolytic activities, biologic functions and structural organization (Chen 2003, Chen 
& Kelly 2003): 
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1. Membrane-type matrix metalloproteinases (MT-MMPs) 
2. Disintegrin and metalloproteases (ADAM family)  
3. Meprins 
4. Secretases 
5. Metallo- and serine peptidases (SIMP) 
 
It is generally known that a given membrane protease may have several functions 
(diversity) and that more than one protease or protease family may mediate the same 
function (redundancy) (Bauvois B 2001). Soluble counterparts of some membrane 
proteases have been found intracellularly as well as in extracellular fluids, including 
blood plasma (Rettig et al. 1988, Sedo et al. 1996, Chiravuri et al. 1999, Abbott et al. 
2000, Tang et al. 2000, Goldstein & Chen 2000, Chen 2003). 
 
Localization of enzymes is critical for their function in cellular activities. It has been 
shown before that MT-MMPS and SIMP may have a prominent role in processing 
soluble factors as well as in degrading the components of the ECM (Sato et al. 1994). 
This study aims to examine this area in more detail and is focused on three members 
of serine protease family which are introduced below. 
 
Seprase / FAP-
 
FAP- was first identified as an inducible antigen expressed on reactive stromal 
fibroblasts (Rettig et al. 1988 & 1993, Garin-Chesa et al. 1990). In parallel, seprase 
was originally isolated as a 170-kDa transmembrane protease from the malignant 
melanoma cell line LOX (Aoyama & Chen 1990, Monsky et al. 1994, Kelly et al. 
1994). Further molecular cloning of FAP- and seprase revealed the identical gene 
and protein (Scanlan et al. 1994, Piñeiro-Sánchez et al. 1997, Chen & Kelly 2003, 
Chen 2003). The gene is localized on the long arm of chromosome 2 (2q23). Seprase / 
FAP- is a type II transmembrane protein of 760 amino acids, anchored in the plasma 
membrane by a short transmembrane domain, intracellularly exposing an amino 
terminal sequence, whereas a catalytic domain with a carboxyl-terminus remains 
extracellularly (Park et al. 1999, Levy et al. 1999). It displays both prolyl dipeptidyl 
peptidase and gelatinase activities. The protease appears as a homodimer (170 kDa) 
containing two 97 kDa subunits. Glycosylation and dimerization of the enzyme are 
necessary for its protease activity (Sun et al. 2002, Kelly 2005). 
 
In humans, seprase has been identified in tissue remodeling sites, reactive stromal 
fibroblast in 90% of malignant epithelial tumors and sarcomas, granulation tissue of 
healing wounds and fetal mesenchymal tissue. The immunopathological expression of 
seprase has previously been investigated in gastric and colon cancer, as well as in 
melanoma, ovarian and breast cancer and its overexpression was associated with 
malignant phenotype (Okada et al. 2003, Iwasa et al. 2003). Sepraseis not expressed 
in normal adult human tissue (Garin-Chesa et al. 1990, Rettig et al. 1993, Scalan et al. 
1994, Ariga et al. 2001). 
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Dipeptidyl peptidase IV (DPPIV, CD 26) 
 
DPPIV was first identified in 1966 as glycylproline naphthylamidase (Hopsu-Havu & 
Glenner 1966). DPPIV is an integral membrane glycoprotein with type II topology. 
Native human DPPIV is a 110 kDa protein, while the active form is a 200-220 kDa 
homodimer that exhibits the dipeptidyl peptidase activity (Piazza et al. 1989, Johnson 
et al. 1993, Piñeiro-Sánchez et al. 1997). The DPPIV structure contains 766 amino 
acid residues. The human gene of DPPIV is localized on the long arm of chromosome 
2 (2q24.3). Peptidase is expressed constitutively on brush border membranes of 
intestine and kidney epithelial cells and transiently in activated T-cells and migratory 
endothelial cells (Vivier et al. 1991, Yaron & Naider1993, Morimoto et al. 1994).  
 
It was shown that DPPIV, in addition to its typical dipeptidyl aminopeptidase activity, 
may possess endopeptidase activity as well (Bermpol et al. 1998). DPPIV expression 
and activity was observed in numerous types of human malignancies (basal cell 
carcinoma, prostate-, ovarian- and thyroid carcinoma) as well as in blood plasma of 
cancer patients (Hirai et al. 1999, Wilson et al. 2005, Ozog et al. 2006). In general, 
higher DPPIV expression is associated with more aggressive tumor behavior. 
 
In contrast, in ovarian carcinoma cell lines, DPPIV overexpression was associated 
with a decrease in invasive potential, change in morphology, reduction of 
intraperitoneal dissemination of carcinoma cells and prolongation of survival time in 
vivo (Kajiyama et al. 2002, Kikkawa et al. 2005). Functional studies have also 
demonstrated that loss of DPPIV expression during malignant transformation of 
melanocytes is accompanied by growth factor independence, whereas its 
experimentally induced re-expression leads to the suppression of tumorigenicity, 
reversal of a block in differentiation and re-emergence of requirements for exogenous 
growth factor (Wesley et al. 1999, Pethiyagoda et al. 2000).  
 
Finally, a soluble form of DPPIV modulating the responsiveness of T-cells to specific 
antigens has been detected in blood plasma (Tanaka et al. 1994). 
 
uPA
 
The serine protease family includes also uPA, a glycoprotein with a molecular weight 
of 55 kDa, known to operate extracellularly. It is activated on the cell surface, binding 
to a specific receptor (uPAR), which is linked to the plasma membrane and may form 
complexes with sepraseDPPIV and 
 integrin. uPA cleaves plasminogen to form 
active plasmin, breaking down most ECM components, including type IV collagen, 
laminin and fibronectin (Hansen et al.1994). 
 
An elevated level of uPA has been involved in the development of invasiveness in 
numerous neoplasms, including breast-, ovarian-, gastric- and colorectal cancer, as 
well as SCC and AC (Nishino et al. 1988, Sier et al. 1991, Hewin et al. 1995, 
Torzewski et al. 1997, Nekarda et al.1998, Artym et al. 2002). 
 32
Serine protease complexes 
 
Former studies have revealed that serine proteases are able to form complexes. Ghersi 
and Dong, for example, have shown that seprase and DPPIV are simultaneously 
involved in the degradation of the collagenous matrix (Ghersi et al. 2002). The two 
proteases form a complex localized at invadopodia of cells migrating on collagenous 
fibers that elicits both endo- and exopeptidase activities (Chen 2003). The complex, 
described as a 400 kDa molecule, develops into a potent ECM degrading factor 
(Piñeiro-Sánchez et al. 1997, Mueller et al. 1999, Ghersi et al. 2002).  
 
Immunoprecipitation, immunofluorescence and cell surface crosslinking experiments 
demonstrated another seprase-DPPIV complex with 
 integrins, additionally 
facilitating invasion into the collagenous matrix (Mueller et al. 1999, Chen 2003). 
Interestingly, 
 integrin is even able to bind uPAR (Zhang et al. 2003). This 
binding demonstrates the possibility of creating a supramolecular complex consisting 
of seprase-DPPIV-uPAR/uPA-
 integrin, exposing common proteolytic activity 
(Scanlan et al. 1994, Ghersi et al. 2002, Artym et al. 2002, Kelly T 2005). 
 
A recent study, performed on HUVEC, has shown a seprase-DPPIV complex (~ 820 
kDa) localized at an invadopodia-like protrusion of endothelial cells involved in the 
invasion of the ECM (Ghersi et al. 2006). In vivo examination on invasive breast 
ductal carcinoma specimens has shown a distribution of the complex on the 
endothelial cells of capillaries, but not on large blood vessels, contributing thus to 
understanding the role of serine proteases in the angiogenetic process (Ghersi et al. 
2006).  
 
A simplified interaction model between the serine proteases, integrins and ECM is 
illustrated in Figure 3. 
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Figure 3. Possible serine protease complex. DPPIV, Fap- uPA / uPAR and 
integrin with 
proteolytic, adhesive and signaling capabilities. The complex may act intra- and 
extracellularly, demonstrating a common enzymatic activity (modified after Kelly 2005). 
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4. AIMS OF THE STUDY 
Little information about expression patterns of the serine protease family members in 
esophageal carcinomas was available when this study was initiated. Though uPA has 
previously been analyzed in esophageal carcinomas, the role of seprase and DPPIV in 
this carcinoma type is not yet known. No systemic study of expression patterns of all 
three serine proteases together in the upper gastrointestinal tract and their clinical 
association was available. Thanks to the fact that the study partly was a collaboration 
project between the Norwegian Radium Hospital, Rikshospitalet HF in Oslo, Norway 
and Anyang Tumor Hospital, Henan Province in China, we were able to collect 
extensive material from this particular tumor type. This gave us the unique 
opportunity to study the expression of serine proteases in normal, premalignant and 
malignant stages of both SCC and AC in order to better understand their involvement 
in neoplastic progression and the possible use as marker of malignant or metastatic 
potential.  
 
Furthermore, from a clinical point of view, no complete report has been published 
until today, assessing patients treated at the Norwegian Radium Hospital, 
Rikshospitalet HF with esophageal carcinoma. Using our clinical databases and tissue 
material, we examined clinical and histopathological information taking into account 
all the esophageal cancer patients treated at the Norwegian Radium Hospital, 
Rikshospitalet HF between 1987-2007 in order to analyze epidemiology, occurrence 
of precancerous stages and treatment results. 
 
The specific aims were to: 
- Compare seprase, DPPIV and uPA expression in dysplastic and cancer cells of 
SCC, as well as in stromal cells adjacent to premalignant and malignant sites 
- Examine seprase and uPA expression in Barrett’s esophagus, dysplasia and AC, as 
well as in stromal cell bordering neoplastic alterations 
- Compare DPPIV expression in cancer and stromal cells of SCC and AC 
- Demonstrate stromal serine protease expression  
- Describe and analyze clinicopathological features of the patients with esophageal 
carcinoma
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5. MATERIALS AND METHODS 
Patients and tissue samples 
 
This study included two independent patient groups:  
1. Norwegian patients who were diagnosed with esophageal dysplasia or esophageal 
cancer in the period from January 1987 until December 2007 and underwent 
periodic surveillance or received partial or complete treatment at the Surgical 
Oncology Department of the Norwegian Radium Hospital, Rikshospitalet HF in 
Oslo, Norway (Papers I, III and IV). 
2. Chinese patients who were diagnosed with esophageal dysplasia or esophageal 
cancer between 2003 and 2005 and underwent periodic surveillance or received 
treatment in Anyang Tumor Hospital, Henan Province, China (Paper II).  
 
Diagnostic tests and surgical or oncological treatments were performed depending on 
the clinical symptoms and on the stage of advancement of the disease, consistent with 
the conventional rules of therapy of esophageal cancer, including ongoing clinical 
trials and accepted palliative care.  
 
Tissue samples of Barrett’s esophagus and dysplasia were obtained from patients who 
underwent diagnostic tests as a result of increasing symptoms of dysphagia or a local 
irritation in the esophagus. Chest and esophageal x-rays with contrast, blood tests and 
endoscopy with a subsequent pathological evaluation of tissue samples were 
performed at the Norwegian Radium Hospital, Rikshospitalet HF and at Anyang 
Tumor Hospital, depending on the samples’ origin. The dysplasia samples were 
obtained by gastroscopy with a flexible gastroscope. They were fixed in formalin, 
embedded in paraffin and stained with haematoxylin and eosin. 
 
Tissue samples of advanced esophageal carcinomas (SCC and AC) were obtained 
from nonoperated patients by gastroscopy (as a diagnostic test before choosing 
treatment) and from patients who underwent potentially curative resection of the 
esophagus (preceded by adequate diagnostic tests) in the above mentioned hospitals. 
Potentially curative resection was defined as removal of all gross tumor tissue, 
histologically confirmed absence of tumor tissue at the surgical margins and absence 
of distant metastases (Torzewski et al. 1997). The patients received either no 
treatment prior to surgery or underwent neo-adjuvant radiotherapy. The gastroscopies 
were carried out using a flexible gastroscope. Esophagectomies were performed 
through laparotomy and a right- or left-sided thoracotomy with an abdominal 
approach through the diaphragm. Subsequent reconstitution was completed mostly by 
means of esophagogastrostomy, using the gastric tube through the retrosternal route, 
with construction of a cervical anastomosis. The surgery samples underwent the same 
fixation procedures as the dysplasia samples and were embedded in paraffin as a 
single sample (Norwegian tissue material), or were stored as tissue arrays (Chinese 
tissue material); each array contained tissue samples from 37 to 70 different patients.  
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As control group, samples of normal esophageal epithelium were collected from 
Norwegian patients, primarily operated at the Department of Surgical Oncology of the 
Norwegian Radium Hospital, Rikshospitalet HF for esophageal cancer between 1993 
and 1999. Tissue samples were taken from normally looking squamous epithelium, 
located >5 cm from the tumor site. These samples were prepared for investigation in 
the same way as the samples described before. No tumor tissue was observed in the 
obtained samples, either macroscopically or microscopically. 
  
In accordance with the WHO (WHO 1990), the dysplasia samples were histologically 
categorized into three groups: low-, moderate- and high grade dysplasia. The WHO 
classification also divides SCCs and ACs into three groups: well-, moderately- and 
poorly differentiated. Clinical classification was completed using TNM staging 
according to UICC Global Cancer Control (UICC 2005). 
 
Cell lines 
 
Cells deriving from well-, moderately- and poorly differentiated esophageal SCC 
respectively (KYSE450, KYSE140 and KYSE70 cell lines), and cells from normal 
esophageal epithelium (HET1A) were used in our study. The cell lines were provided 
by Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Braunschweig, Germany. 
 
Antibodies
 
We used the following antibodies in our experiments: 
- Rabbit polyclonal antibody, isotype IgG, directed against human FAP-, 
purchased from Abcam, Cambridge, UK 
- Monoclonal rat antibody (clone E26), directed against the 200-220 kDa form of 
DPPIV obtained from Prof. W-T Chen (Department of Medicine, State University 
of New York, Stony Brook, N.Y., USA) 
- Anti-human dipeptidyl peptidase IV, polyclonal goat antibody, obtained from 
R&D Systems, Minneapolis, MN 
- Rabbit polyclonal antibody, directed against human HMW-scuPA (54 kDa), 
HMW-tsuPA (52 kDa) and LMW-scuPA (33 kDa), purchased from Abcam, 
Cambridge, UK 
 
Laboratory methods  
Immunohistochemistry
Tissue samples were fixed in 4% buffered formalin, embedded in paraffin, cut at four 
microns, dried in the oven at 70 °C overnight before deparaffinization and rehydration 
through decreasing concentrations of alcohol to running tap water. The slides required 
no pre-treatment. The EnVision+ system from Dako Cytomation was used according 
to the kit manual, and haematoxylin was used for counterstaining. Appropriate 
 38
negative and positive controls were applied according to the antibodies’ specificity 
(M&M, papers I-III). 
Semi-quantitative analysis of immunohistochemistry 
The seprase-, FAP--DPPIV- and uPA expressions were semi-quantified using a 
visual grading system in which the staining intensity was categorized into four 
groups; 0, 1+, 2+, 3+, where group 0 was defined as having a complete absence of 
staining. Groups 1-3 were defined as groups with positive staining of increasing 
intensity as compared to the positive control. The number of positive cells was also 
categorized into four groups, where group 0 was defined as total absence of positive 
cells, and groups 1-3 were defined as groups with positive cells counted in 
percentages; 0 = 0%, 1 = <25%, 2 = 25-50%, 3 = >50%. The outcome was calculated 
by multiplying the corresponding values from staining intensity by the number of 
positive cells and was subsequently divided into four final groups: 0, 1+, 2+ and 3+. 
 
In order to guarantee quality control, two independent pathologists performed the 
sample interpretation separately. Diverging cases were discussed until an agreement 
was reached. 
Immunoblotting
Cells from cell lines were lysed in cold TGH buffer (1% Triton X-100, 10% glycerol, 
20mM Hepes, pH 7.2, 100mM NaCl) containing 1mM phenylmethylsulfonyl fluoride, 
10g/ml leupeptin and 1mM Na3VO4. After shaking, the lysate was incubated for 60 
min at 4 oC with rocking. Insoluble materials were removed by centrifugation (14.000 
rpm x g, 20 min) at 4 oC, and the supernatant was collected. Total protein 
concentration in each sample was estimated with the Bradford analysis (Bio-Rad). 
SDS-PAGE was performed in 12% gels as described by Laemmli (Laemmli 1970), 
and the proteins in the gel were transferred to a polyvinylidene difluoride (PVDF) 
membrane (Immobilon-FL, Millipore, Bedford, MA). After one h blocking with 5% 
non-fat dry milk powder in TBS (TRIS Buffered Saline consisted of 137 mM NaCl, 
25 mM TRIS and 2.7 mM KCL, pH 7.6) containing 0.05% Tween-20, the membranes 
were incubated at 4 oC overnight with tested antibodies at adequate dilution. The 
membranes were then washed three times for 10 min with PBS (Phosphate Buffered 
Saline consisting of 137 mM NaCl, 12 mM phosphate and 2.7 mM KCL, pH 
7.6)/0.1% Tween-20 and finally incubated with the appropriate secondary antibody 
conjugated to horseradish peroxidase for one h at room temperature. The membranes 
were then again washed three times for 10 min with TBS/0.05% Tween-20. A 
chemiluminescent detection reagent (ECL Plus, Western blotting detection system, 
GE Healthcare) was used for peroxidase signal detection. To ensure equal loading of 
proteins, the same membranes were reprobed with rabbit polyclonal anti ERK-2 (SC-
154) antibody (Santa Cruz Biotechnology, CA, USA) at dilution 1:50000 in 5% milk. 
Quantitative real-time RT-PCR analysis 
Total cellular RNA was extracted from cell lines (KYSE450, KYSE140, KYSE70 and 
HET1A) using the TRIZOL reagent (Invitrogen, Carlsbad, CA). The high capacity 
cDNA reverse transcription kit (Applied Biosystems, Foster City, CA) was used to 
reverse-transcribe obtained RNA (0.8 g) in a 20 μl reaction mixture using random 
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primers. The real-time PCR analyses were performed using TaqMan Fast Universal 
PCR Master Mix and TaqMan Gene Expression Assays for FAP- DPPIV, uPA and 
GUS (Applied Biosystems). A total of 5 μl cDNA, diluted at 1:10, was used in 25 μl 
PCR mixtures with 900 nM of each primer and 250 nM TaqMan probe. The reactions 
were carried out in a 7900HT Fast Real-time PCR system (Applied Biosystems) with 
the following program: 95 oC for 20 s followed by 40 cycles of 95 oC for one s, 60 oC 
for 20 s. Each sample was run in triplicate. The threshold cycle (CT) values of the 
amplification reactions were determined automatically using RQ Manager 1.2 
software (Applied Biosystems). The FAP-DPPIV and uPA relative mRNA 
expression level was normalized with respect to the beta-glucuronidase (GUS) gene, 
which had stable transcript levels under these experimental conditions. The tumor / 
normal ratio of the normalized target transcript expression was calculated by means of 
the 2-C method (Livak & Schmittgen 2001) from three independent experiments.  
Enzymatic activity biochemical assay 
For enzymatic activity assays, near-confluent cells from KYSE450, KYSE140, 
KYSE70 and HET1A cell lines were incubated for 18 h in fresh medium (RPMI 1640, 
Invitrogen) containing 1% FCS. Then, media were collected and cells were lysed in 
lysis buffer (0.1 M NaCl, 10 mM Na2HPO4, 1% Triton X-100, 1 mM EDTA). The 
DPPIV-like activity was assayed by measuring the cleavage of Gly-Pro-NH-Np 
substitute (Gly-Pro-4-nitroaniline, Sigma) at pH 8.0 by either cell lysate or medium 
collected from cells after 18 h incubation, according to the standard procedure 
provided by Sigma. Twenty-five l of sample (medium or lysate) were incubated in 
0.1 M Tris (pH 8.0) with 0.5 mM Gly-Pro-NH-Np in a total volume of 200 l at 37 C 
for different time points in flat-bottom 96-well microplates. Activity was determined 
by measuring absorption at 405 nm with Biotrak Microplate Reader (Amersham). 
uPA activity was measured in an analogous way (using the chromogenic substrate) 
with the CHEMICON uPA Activity Assay Kit. Total protein concentration in samples 
was assayed by the Bradford method (Bradford 1976). 
Statistical analysis 
Associations between variables were assessed using Chi-square tests (Pearson and 
linear-by-linear association). Differences between quantitative variables in 
independent groups were tested by Mann-Whitney tests. They were all two-sided 
tests. Comparison of survival between the groups was performed using log-rank tests. 
Survival curves were calculated with the Kaplan-Meier product-limit method. A p-
value of <0.05 was considered statistically significant. Statistical analyses were 
performed using SPSS 13.0 and 15.0 for Windows. 
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6. SUMMARY OF PAPERS 
PAPER I 
DPPIV is a transmembrane serine protease involved in the process of tumor invasion 
and development of metastasis in human cancers. In this article we investigated the 
expression of DPPIV in cancer and stromal cells of both esophageal AC and SCC. We 
analyzed tissue material from 159 patients treated in our hospital between January 
1987 and November 2002 (SCC (n=90) and AC (n=69)) using 
immunohistochemistry. The patients were divided into two groups to obtain more 
specific results: irradiated and non-irradiated patients (n=46 and n=113 respectively).  
 
We also performed Western blotting on SCCs and normal esophageal epithelium cell 
lines, as well as on fresh frozen tissues from ACs and normal esophageal epithelium. 
Results of immunostaining were compared with the patients’ clinicopathological 
features. 
 
Immunohistochemistry of the whole population revealed differences between DPPIV 
expression in AC and SCC cells: DPPIV expression was higher in ACs than in SCCs. 
In contrast, DPPIV expression in stromal cells was higher in SCC stroma than in AC 
stroma. In the whole population, DPPIV was also significantly associated with lymph 
node metastases, distant metastases and age. The expression pattern revealed that a 
high expression of DPPIV involved a higher risk of distant- and lymph node 
metastases. The correlation between DPPIV expression and age was proportionally 
inverted: carcinoma cells of older patients contained a lower level of protease. 
 
The separate analyses of SCC and AC showed a correlation between the expression of 
DPPIV in cancer cells and distant metastases only in the AC group. We did not find 
any associations between DPPIV expression in cancer cells and clinicopathological 
features in SCCs.  Further analyses of the two groups showed no associations between 
DPPIV expression in stromal cells and clinicopathological features. Radiotherapy had 
no impact on DPPIV expression in the analyzed tissue samples. There was no 
correlation between DPPIV expression in cancer or stromal cells and survival of the 
patients. 
 
Immunoblotting did not show any detectable DPPIV in the cell line originating from 
normal esophageal epithelium or fresh-frozen tissue samples of normal esophageal 
epithelium. In contrast, DPPIV was present in all carcinoma samples. SCC cell lines 
showed a decreasing intensity of DPPIV from well to poorly differentiated 
carcinomas. In the fresh-frozen cancer tissue samples, the highest DPPIV expression 
was detected in moderately differentiated carcinomas. Poorly and well differentiated 
carcinomas showed a lower expression of DPPIV.
 
Thus, differences in the DPPIV level in esophageal carcinomas compared with normal 
epithelium showed that esophageal malignancies were associated with an increased 
amount of cell surface-bound DPPIV. 
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PAPER II 
 
In an attempt to elucidate the role of the serine proteases seprase, DPPIV and uPA in 
the degradation of the ECM and in the progression of esophageal SCC, we studied the 
expression of the proteases in esophageal dysplasia, invasive carcinomas and normal 
epithelium by using immunohistochemistry. Tissue samples from different stages of 
dysplasia (n=85) and from advanced SCCs at different stages (n=144) were obtained 
from patients treated at Anyang Tumor Hospital, Henan Province in China. 
Additionally, we performed real-time RT-PCR, Western blotting and enzymatic 
activity biochemical assays on cell lines originating from different SCC grades and 
from normal esophageal epithelium. 
 
Seprase, DPPIV and uPA immunoreactivity were demonstrated in dysplastic and 
cancer cells as well as in stromal cells adjacent to dysplasia and cancer sites, but not 
in normal epithelium. A significant association between uPA expression and sex, 
tumor size and histological classification in carcinomas was shown. Increased 
expression of DPPIV in cancer cells correlated with longer patient survival. 
Furthermore, no significant associations between seprase and clinicopathological 
features either in dysplasia or in carcinomas could be found. Finally, using Western 
blotting, real-time RT-PCR and enzymatic activity assays, we demonstrated higher 
levels of the proteases in SCC cell lines than in normal esophageal epithelial cell 
lines.  
 
These results showed that seprase, DPPIV and uPA were expressed in both 
premalignant and malignant forms of SCC, but lacking in normal esophageal 
epithelium, confirming thus their involvement in the SCC neoplastic progression. This 
fact indicates the possibility that these serine proteases play a role in the 
transformation from normal to dysplastic epithelium. 
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PAPER III 
 
We examined FAP-and uPA expression in premalignant and malignant stages of 
esophageal AC by immunohistochemistry. The findings were compared with 
clinicopathological features. Tissue samples of Barrett’s esophagus with and without 
dysplastic changes were obtained from 22 patients, whereas tissue samples of 
irradiated and non-irradiated ACs of different histological grades were collected from 
69 patients. We also performed Western blotting on fresh-frozen tissue samples 
obtained from both carcinoma tissue and normal esophageal epithelium.  
 
There were no significant associations between the protein expressions in metaplastic 
and dysplastic cells and the histological grading or development of cancer. In contrast, 
stromal uPA expression was significantly higher in metaplastic and low- / moderate 
grade dysplasia than in high grade dysplasia. No such association could be found for 
FAP-. 
 
We did not find any correlations between FAP-and uPA expression and 
clinicopathological features in carcinoma cells. Division of AC patients into two 
subgroups, irradiated patients (n=18) and non-irradiated patients (n=51), did not 
reveal any changes in the analyses. 
 
Examination of the stromal protease expression on the other hand, exhibited 
significant correlations between FAP-and depth of tumor invasion, as well as uPA 
and lymph node metastasis. High stromal FAP-expression was detected in T1 
tumors, compared to a low FAP-activity in T2-T4 tumors. Stromal uPA 
overexpression was found in tissue samples of patients without lymph node 
metastases, while low uPA expression was associated with lymph node metastases.  
 
The analysis of patients relating to radiotherapy revealed that non-irradiated patients 
had a higher stromal FAP-concentration than irradiated patients. 
  
We did not find any correlation between FAP-or uPA expression and survival of the 
patients, but due to the modest number of patients, a type II error can not be excluded. 
 
Immunoblotting showed higher protease expression in carcinoma tissues than in 
normal esophageal epithelium.
 
These results suggest that FAP-and uPA expression in metaplastic, dysplastic and 
esophageal cancer tissue, including stroma adjacent to cancer sites, is associated with 
the early neoplastic progression of esophageal lesions. 
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PAPER IV 
 
Esophageal cancer is not a common cancer in Norway, but remains a problem due to 
low survival rates and considerable treatment morbidity. We analyzed and compared 
clinical and pathological data of patients treated at the Norwegian Radium Hospital,
Rikshospitalet HF, Oslo, during the last two decades (1988-1997 and 1998-2007). 
During the last 20 years, we observed a significant change in the occurrence of 
esophageal SCCs in relation to ACs in the Norwegian population. The AC incidence 
has increased from 5-10% to more than 50% in the last decade, while the incidence of 
SCCs has decreased. Additionally, a change in the pattern has also been observed: 
ACs occur in younger patients and are primarily related to GERD.  
 
An important aspect of this two-decade study was to evaluate the general impact of 
anti-reflux therapy and surveillance of premalignant lesions and if this could be 
reflected in tumor stage, patient demographics and treatment results. This was not a 
randomized study but it gave us a possibility to get an impression of the effect of 
preoperative radiation on some biological markers and on the final treatment outcome, 
survival and recurrence rates. Based on the observations of our patients, we concluded 
that no significantly improved survival could be demonstrated from preoperative 
irradiation, but a trend towards improvement was seen. Finally, we found that the 
change from SCC to AC did not lead to improved long time survival in our patients. 
 
Our results allowed us to observe that the most important epidemiological difference 
between SCC and AC is the strong association between GERD and AC. Furthermore, 
Barrett’s esophagus was clearly associated with AC in more than one-fourth of the 
cases and probably in a lot more due to the fact that small Barrett’s lesions are often 
completely supplanted by tumor tissue. Almost all patients suffered from dysphagia or 
dysphagia-related symptoms at the time of diagnosis, demonstrating that even for AC, 
usually in the distal esophagus, this is a late symptom. A very modest increase in early 
cancer lesions referred in the last decade demonstrates that an increased vigilance of 
GERD-induced lesions may be of importance for decisive local treatment instead of 
esophagectomy following dysphagia diagnosed advanced tumors. 
 
In conclusion, upcoming studies should focus on developing strategies for early 
detection of the disease, using specific markers appearing in precancerous stages, 
separating thus completely or partially premalignant from malignant stages. 
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7. GENERAL DISCUSSION 
The serine proteases’ ability to degrade the ECM is considered to be a prerequisite for 
invasion and spreading of cancer cells (Duffy 1987, Zukker 1988, Birkedal-Hansen 
1995, Hewitt & Danø 1996). Numerous factors are involved in this process, but the 
direct and indirect interaction between the proteases and the basement membrane 
seems to play a pivotal role in the initiation of tumor cell invasion (Duffy 1987).  
 
Previous studies on serine proteases focused mainly on enzymes derived from tumor 
cells (Nishino et al. 1987, Torzewski et al. 1997, Kikkawa et al. 2004). Recently, 
however, enzymes produced by stromal cells bordering tumor sites have also been 
considered as a strong factor implicated in tumor progression (Iwasa et al. 2003, Mori 
et al. 2004). Although serine protease expression has been investigated in several 
carcinomas, there is still limited knowledge about their presence in esophageal 
malignancies.  
 
Thanks to our collaboration with Anyang Tumor Hospital in China, we have access to 
a large series of esophageal carcinomas allowing us to study serine protease 
expression in premalignant and malignant stages of both SCC and AC. SCC, 
previously considered a dominant form of esophageal cancer worldwide, shows today 
a slightly decreasing incidence in the Western world, while it remains the major 
esophageal carcinoma type in the developing countries (Devesa et al. 1998, Blot & 
McLaughlin 1999). The SCC occurrence in certain areas of Asia or Africa is so high 
that screening programs could be considered a method for detecting premalignant and 
early stages of carcinoma, trying thus to reduce mortality among specific populations 
(Sammon 1998, Saidi 1999, Wang et al. 2002, Yang et al. 2002,). The Western world, 
on the other hand, suffers from increasing numbers of AC, whose association with 
GERD and Barrett’s esophagus is commonly known. The latter could be considered a 
premalignant stage and by many suggested to undergo strict surveillance (Blot & 
McLaughlin 1999, Lagergren et al. 1999). The long-time effects on survival from 
esophageal cancer of such surveillance regimens have so far not been convincingly 
demonstrated. 
 
We still believe that monitoring precancerous stages is important for early detection 
and local intervention and thus reducing mortality and morbidity. No blood test has 
yet been found which could distinguish premalignant from malignant stages. 
Histological biopsies and morphological evaluation still remain the major diagnostic 
methods (Dong et al. 2002).     
 
In the current study, we focused on the analysis of three interesting indicators  
(seprase / FAP-DPPIV and uPA) and their possible role in the evolution of 
premalignant and malignant stages of both major types of esophageal carcinoma, SCC 
and AC. We compared their expression levels with clinicopathological features in a 
series of patients, using the clinical databases of the two previously mentioned cancer 
hospitals (papers I-III). 
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The analysis of clinical information related to Norwegian patients (Paper IV) has 
given a substantial insight into the rapidly changing esophageal carcinoma 
epidemiology in Norway and our diagnostic and treatment methods over the last two 
decades. Both pathological and clinical studies contributed to a better understanding 
of the evolution and differences between the two types of esophageal carcinomas and 
their premalignant stages. Results obtained from histopathological and biochemical 
studies pointed to the identification of possible markers that could be used in future 
clinical work to characterize precancerous stages as well as invasive cancers.  
Main findings 
Main findings concerning the expression of serine proteases in the analyzed tissue 
samples: 
 Seprase, DPPIV and uPA immunoreactivity was found in dysplastic and SCC 
cells as well as in stromal cells adjacent to dysplasia and cancer sites, but not in 
normal epithelium (Paper II). 
 A significant association between uPA expression in carcinoma cells and sex, 
tumor size and histological classification in SCCs was found. 
 High expression of DPPIV in carcinoma cells correlated with longer survival 
of the patients with SCC. 
 No significant associations between seprase expression and
clinicopathological features either in dysplasia or in carcinomas were found. 
 SCC cell lines had higher levels of seprase, DPPIV and uPA than normal    
esophageal epithelial cell lines. 
 DPPIV displayed a significantly higher level in ACs as compared to SCCs, while 
no DPPIV was detected in normal esophageal epithelium (Paper I).
 Cellular overexpression of DPPIV in patients with AC was associated with 
distant metastases. 
 Radiotherapy in patients with SCC or AC had no impact on DPPIV expression 
in the analyzed tissue samples. 
 Seprase and uPA were detected in metaplastic-, dysplastic- and AC cells, as well 
as in stroma bordering metaplasia-, dysplasia- and carcinoma sites (Paper III). 
 Stromal seprase expression was associated with depth of tumor invasion, 
while stromal uPA expression correlated with lymph node metastases in AC. 
 Stromal uPA expression in cells with dysplasia correlated with histological 
grading.
 Higher protease expression in AC cells than in normal esophageal epithelium 
was found. 
 
Main findings concerning the analyses of the clinicopathological material from 
referred patients (Paper IV): 
 Esophageal cancer showed an increased occurrence of AC in the distal part of the 
esophagus and, in the last two decades, was frequently associated with Barrett’s 
esophagus in the Norwegian population. 
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 No significantly improved survival of the patients could be demonstrated from 
preoperative irradiation, but a trend towards improvement was seen. 
 The change from SCC to AC did not lead to improved long time survival of the 
patients. 
 
Serine proteases in dysplastic-, cancer- and stromal cells of SCC and AC 
When analyzing tissue samples of different stages of dysplasia evolving into SCC 
(Paper II), we detected the strongest serine protease immunostaining in grade III 
dysplastic cells (carcinoma in situ) and the weakest in grade I, which turned out to be 
a common pattern for all three enzymes. The same staining pattern was also found in 
stromal cells adjacent to dysplasia sites, while normal epithelium did not show any 
staining at all. Considering the absence of serine protease expression in normal 
epithelium, the point of transformation from normal to dysplastic epithelium may be 
crucial for the activation of serine proteases, and, subsequently, their extracellular and 
pericellular proteolytic activities. Furthermore, the activity, or most likely, the 
production of serine proteases in both dysplastic cells and stromal cells adjacent to 
dysplasia increased in parallel to the advancement of dysplasia, showing a clear, 
positive association between the serine protease level and the degree of 
premalignancy. Finding serine proteases in premalignant and stromal cells indicates a 
close relationship between dysplastic and stromal cells, where dysplastic cells 
possibly stimulate stromal cells to generate e.g. serine protease activity. In relation to 
this and to what will be discussed further below, we thus concluded that serine 
proteases contribute to all stages of both premalignant and malignant progression in 
SCCs, and not only to the latter, as was previously suggested (López-Otín & 
Matrisian 2007). 
 
On the other hand, when focusing on the expression of seprase and uPA in Barrett’s 
metaplasia and dysplasia, eventually developing into AC (Paper III), no apparent 
association between protease expression and dysplasia stage could be identified, 
although the presence of proteases was evident in both dysplastic and stromal cells. 
Like in the case of SCCs, this finding too points towards an interplay between 
premalignant and stromal cells in this kind of carcinoma. It is noteworthy that this 
common trait concerned two histologically different premalignant conditions. With 
regards to this finding, we believe that the transmembrane proteases exist as signaling 
molecules on dysplastic cells and stromal cells adjacent to dysplasia in precancerous 
stages of both SCC and AC, probably interacting with other molecular factors 
exhibiting enzymatic activity, contributing to the development of invasive 
carcinomas.  
 
The common immunostaining pattern for all tested proteases observed in dysplastic 
and stromal cells (Paper II) supported former studies, indicating the presence of 
supramolecular complexes such as seprase-uPA, seprase-DPPIV or even seprase-
DPPIV-uPA on the cell membrane (Fig. 3) (Scanlan et al. 1994, Ghersi et al. 2002 & 
2006, Chen & Kelly 2003, Kelly 2005). Although we did not specifically investigate 
the presence of such complexes in dysplastic or stromal cells, the similar enzymatic 
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activity of all three proteases detected in DPPIV-like and uPA enzymatic activity 
assays performed on cell lines reinforced the hypothesis about serine protease 
complexes. 
 
Analysis of DPPIV alone in carcinoma cells (Paper I) showed that DPPIV expression 
was significantly higher in ACs than in SCCs, indicating that tumors originating from 
histologically different epithelial types may influence the production or expression of 
protease to a different degree. We presume that metaplasia occurring in the distal 
esophagus, where columnar cells replace stratified epithelium, and where dysplasia 
and AC frequently develop, significantly enhances DPPIV production in affected 
cells. This assumption is in agreement with Chaves’ study (Chaves et al. 1999) in 
which she detected DPPIV in Barrett’s esophagus and AC related to it, thus showing a 
direct association between these two conditions. Enhanced protease production may 
even be a necessary condition for the metaplastic process per se. The lower level of 
DPPIV found in SCCs in our study does not lessen the proteases’ role in the 
development of this carcinoma type, but indicates that, in addition to DPPIV, other 
cell-surface-associated proteolytic enzymes could strongly be involved in the growth 
of SCCs, or, that SCCs require less DPPIV activity compared to ACs in order to 
develop equal invasive potential. 
 
Furthermore, we found that DPPIV was also present in stromal cells bordering cancer 
sites (Paper I), similarly to previously mentioned findings in dysplastic changes. 
Stromal DPPIV presence in SCC, as well as in AC tissue samples, may indicate that 
cancer cells of histologically different carcinoma types can even influence adjacent 
stromal cells and initiate an additional stromal production of proteases. This finding is 
similar to other studies showing the presence of the DPPIV homologue, seprase, in 
fibroblasts, macrophages and endothelial cells adjacent to tumor sites in human 
gastric and colorectal cancer, where stromal seprase expression was associated with 
lymph node and liver metastases (Iwasa et al. 2003, Okada et al. 2003, Mori et al. 
2004). Our results indicate that stromal DPPIV (no association between stromal 
DPPIV and clinicopathological features) is probably not directly, or only modestly 
responsible, for ECM degradation in esophageal carcinomas. It could rather be a 
useful activator of other enzymes, i.e. metalloproteinases or DPPIV-associated serine 
proteases which serve as workhorses.   
 
Investigation of seprase, DPPIV and uPA occurrence in SCCs (Paper II) and of    
FAP-and uPA in ACs (Paper III) showed again expression of the serine proteases 
not only in carcinoma cells but also in neighboring stromal cells. The 
immunoreactivity of uPA and DPPIV in SCC cells was characterized by a decreasing 
intensity pattern from well differentiated towards poorly differentiated carcinomas. As 
for seprase, although anexpression of more than 93% was observed in SCC samples, 
we could not demonstrate any distinct expression pattern. AC cells, in contrast, 
despite abundant FAP-and uPA presence, showed no correlation between serine 
protease expression and carcinoma advancement (Paper III). Interestingly, stromal 
FAP-and uPA expression was inversely correlated to T and N and, in consequence, 
to tumor progression in general. 
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We suggested previously that cancer cells are able to stimulate the production of 
proteases and other enzymes essential to ECM degradation in stromal cells, which is 
consistent with other studies (Sawhney et al. 1992, Iwasa et al. 2003). The stromal 
serine protease expression could also originate from serine proteases which are mainly 
produced by cancer cells and may attach to stroma during their activation (Chen et al. 
2006). Regardless of the cause of its expression, stromal protease expression denotes 
that stroma is able to partly assume control over the serine protease production in 
advanced cancer stages, possibly as a result of a reduced serine protease production in 
highly undifferentiated carcinoma cells. Intensification of such stromal behavior may 
be dependent on the carcinoma histology. For example, the fact that DPPIV and uPA 
expression in SCC cells decreases, whereas tumor aggressiveness increases, clearly 
illustrates this aspect (Paper II). A question arises at this point: do stromal cells take 
over the serine protease production from poorly differentiated carcinoma cells in 
SCCs and thus act as a major factor contributing to tumor invasion in highly invasive 
carcinomas?    
 
As for ACs, lower stromal FAP- and uPA expression positively correlated with 
tumor invasion and lymph node metastases, indicating that AC cells still possess more 
control than stromal cells concerning the serine protease production. This hypothesis 
is supported by results where DPPIV expression in stromal cells was greater in SCCs 
than in ACs and in cancer cells lower in SCCs than in ACs (Paper I). We showed thus 
an obvious difference in the serine proteases’ biological behavior in two histologically 
different esophageal carcinomas. This conclusion derives from analyses of both 
carcinoma cells and stromal cells adjacent to cancer sites, the latter seeming to play a 
more important role in neoplastic progression than was previously assumed (López-
Otín & Matrisian 2007). 
 
Considering the fact that the analyzed serine proteases all belong to one family, that 
DPPIV and seprase share nearly 50% of sequence identity and that the enzymatic 
activity assay results performed on esophageal carcinoma cell lines and normal 
esophageal epithelium were similar for all three enzymes, we presume that the 
proteases operate in an analogous way regarding ECM degradation. Altogether, these 
findings point to a complex interaction between the serine proteases themselves and 
between premalignant, malignant and stromal cells in the development of neoplastic 
process.  
 
The serine protease involvement in tumor progression appears to be evident. Previous 
studies presented them mostly as tumor promoters (Hewin et al. 1996, Cheng et al. 
1998, Iwasa et al. 2003). However, contradictory findings concerning DPPIV, 
exposing it as a tumor suppressor, were also reported (Wesley et al. 1999, 
Pethiyagoda et al. 2000, Kikkawa et al. 2005), whereas seprase and uPA were only 
associated with an increased tumorigenicity. In our study, we observed that high uPA 
and DPPIV expressions in SCC cells correlated with a better prognosis (Paper II), 
which corresponds to the tumor suppressor hypothesis. However, this finding has to 
be interpreted with caution, as we cannot exclude the possibility that even stromal 
serine protease in carcinomas may significantly contribute to preserving their 
malignancy and thus tumor development. In such a case, it is important that not only 
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malignant but also stromal cells adjacent to lesions be analyzed for protease 
expression.  
 
In our study we have analyzed three proteins considered to be important in tumor 
invasion and as prognostic markers. However, many other molecular factors are 
involved in neoplastic progression. Recently, many potential predictive and / or 
prognostic markers for esophageal carcinoma have been identified (Vallböhmer & 
Lenz 2006). For example, the p53 molecule, with major functions in regulating 
apoptosis and in G1-S cell cycle transition, is early and often mutated in SCCs and 
ACs (Shimada et al. 2000). Rb and p16, central regulators of the G1 cell cycle check 
point, are also altered in both histological esophageal carcinoma subtypes (Roncalli et 
al. 1998, Sturm et al. 2001). Human epidermal growth factor receptor 1 seems to be a 
reliable prognostic and predictive marker in esophageal cancer patients (Mendelsohn 
& Baselga 2000 & 2006, Miyazano et al. 2004). Alterations of other markers, such as 
angiogenetic (b-FGF, TGF-TGF-VEGF and Cox-2) or apoptotic (Bax) markers 
are frequently associated with the overall outcome of SCCs and ACs (Inoue et al. 
1997, Shih et al. 2000, Aloia et al. 2001, Ikeguchi et al. 2001, Sturm et al. 2001, 
Shimada et al. 2001, Ogata et al. 2003, Fukai et al. 2003, Kuo et al. 2003, Kleespies et 
al. 2004, Han et al. 2005). As for the transmembrane protease family, MMP-2, MMP-
7 and MMP-9 were studied in esophageal cancer and found to be negative prognostic 
indicators (Tanioka et al. 2003, Ishibashi et al. 2004, Sharma et al. 2004). Thus, 
despite the indisputable biological importance, the value of these and several other 
investigated molecules as clinical biomarkers for prognosis, prediction and early 
detection is still under evaluation. 
 
Clinical study interpretation  
 
The trend in the incidence rates of esophageal cancer generally increased in the last 
two decades in many Western countries. While rates for esophageal SCC remained 
stable or increased slightly, occurrence of AC in the distal esophagus augmented 
significantly. At the time of diagnosis, most esophageal cancer patients already suffer 
metastatic disease (Layke & Lopez 2006, Stoner et al. 2007). This results in a poor 
prognosis: only one of five esophageal cancer patients survives more than three years 
after initial diagnosis (Younes et al. 2002, Polednak 2003, Stoner et al. 2007). 
We observed a distinct trend of increasing esophageal AC and decreasing SCC in the 
referred population during the last 20 years. In order to evaluate the rate, risk factors, 
advancement and treatment of both esophageal carcinomas, we analyzed the clinical 
data and cancer tissue samples of 347 patients treated in our hospital between 1988 
and 2007. We wanted to know if the change in carcinoma type influenced survival 
from esophageal cancer in the last two decades.  
Our observations confirmed the previously mentioned tendency of increasing 
esophageal AC and slightly decreasing SCC. This is consistent with other studies in 
Europe and in the USA (Devesa et al. 1998, El-Serag et al. 2002, Brown et al. 2008). 
We found that over one-fourth of patients with AC reported a Barrett’s esophagus 
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history, mostly connected to GERD symptoms. Also, AC was diagnosed more 
frequently among young patients (30-55 years) (Paper IV). As for SCC, tobacco and 
alcohol were the two most recognized risk factors. This significant change in tumor 
type seems to be strongly related to changes in Norwegian lifestyle. In the last 
decades, the total number of smokers constantly diminished, whereas increasingly 
more Norwegians suffer from obesity (FHI 2004 & 2007, SSB 2008). Weight gain 
has been postulated to enhance gastroesophageal reflux, which can lead to a sequence 
of changes from Barrett’s metaplasia to dysplasia and cancer.   
In Norway, treatment of GERD has been taken seriously, and considerable resources 
have been allocated to this problem. If the diagnosis is made, treatment with proton 
pump inhibitors (PPI) is refunded by the health authorities. Endoscopy and regular 
follow-up with biopsies of Barrett’s changes and dysplasia are recommended as well 
as surgery when drug therapy does not alleviate symptoms or mucosal changes 
develop further. However, despite these efforts, while surgical and medical treatment 
of the symptoms is generally available and almost free of charge, we could not 
demonstrate any significant improvement, neither in the survival of esophageal cancer 
in general or in the subgroup of AC. 
Identification of genetic changes within families with increasing cancer incidence is 
important, and diagnostic methods should focus on the development of strategies for 
early detection of neoplastic malformations, using specific markers emerging in 
precancerous stages. This could give us information about the disease advancement 
and thus help us to determine an appropriate local treatment.   
Since we do not yet have any specific molecular markers characteristic for esophageal 
carcinoma, we should focus on the serine proteases which seemed to play an 
important role in the progress of esophageal malignancies. The detection of both  
FAP-and uPA in precancerous stages of AC (Paper III) confirmed previous results 
describing the involvement of serine proteases in neoplastic progression from its very 
beginning and their proteolytic activity already in full progress in metaplastic and 
dysplastic cells. Interestingly, we also detected expression of seprase, DPPIV and 
uPA in stromal tissue adjacent to dysplastic sites. The staining intensity in stroma 
increased in parallel with the changes in dysplastic cells, with strongest stromal 
staining in grade III dysplasia (Paper II). This finding corroborates a coherence 
between stromal and dysplastic cells in cancer evolution. Here, the question is rising: 
is it possible to keep precancerous stages under surveillance by monitoring the 
molecular marker levels in biopsies? An affirmative answer should be formulated 
carefully, as much more research is needed to define to which degree the proteases are 
involved in the evolution of precancerous stages.  
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8. CONCLUDING REMARKS AND PERSPECTIVES 
 
The low survival rate of esophageal cancer has not been improved during the last 
decade. 
 
ACs have replaced SCCs as the most common type of esophageal cancer being treated 
with curative intention. This has not improved the low long-time survival rate from 
esophageal cancer, neither in our reference hospital nor in the national population. 
Improved neo-adjuvant regimens seem to be able to improve the survival rate 
significantly, but not to a large extent and with a considerably increase in cost and 
morbidity. Without a change towards early diagnosis, most patients will be candidates 
for palliative treatment. Our clinical results demonstrate that, as long as dysphagia and 
dysphagia-related symptoms are the diagnostic starting points, this will more or less 
continue to be the case. 
 
We firmly believe that early diagnosis, combined with local treatment regimens, is the 
best strategy for improvement. The rapid increase in ACs in the Western world 
population is closely connected to symptomatic reflux and a slow development of 
precancerous lesions. Thus, aggressive treatment of reflux, either by means of anti-
reflux surgery or efficient drug treatment, is mandatory. Dysplastic lesions are able to 
continue their development towards cancer, even after efficient anti-reflux therapy. 
Strict surveillance of such lesions by morphological and biological parameters is 
essential and should lead to local treatment of areas demonstrating development 
towards cancer or severe dysplasia. An efficient combination of biological markers is 
still elusive. The membrane proteins studied in this thesis have given us new 
knowledge of esophageal cancer development, but alone, they do not have the ability 
to detect lesions developing towards cancer and would have to be combined with 
other markers. The endeavour towards the most efficient combination of new and 
already characterized markers will have to continue.  
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